The Danish pharmaceutical company Lundbeck is suspected of having prevented market entry of the generic version of its anti-depressant citalopram. Following the opening of proceedings, in January 2010, the European Commission informed the company, on...
Identification
Bonjour, l'accès à cet article est réservé aux abonnés. Veuillez vous identifier dans le cadre ci-dessous.
Commission to introduce mandatory accessibility features - 04/12/2012
Dalli affair: MEPs call for explanation - 04/12/2012
Commission to introduce mandatory accessibility features - 
